Avacta to Spotlight Tumor-Targeted Oncology Platform at TD Cowen Conference

Avacta Group plc ( (GB:AVCT) ) has provided an announcement.

Avacta Therapeutics, part of Avacta Group plc, is a clinical-stage biopharmaceutical company developing the pre|CISION tumor-activated oncology delivery platform to enhance the targeting of highly potent cancer therapies. The company’s pipeline centres on pre|CISION peptide drug conjugates and Affimer drug conjugates that leverage fibroblast activation protein in solid tumors to release active payloads locally and minimize systemic toxicity.

Avacta announced that CEO Christina Coughlin and CFO Brian Hahn will represent the company at the 46th Annual TD Cowen Health Care Conference in Boston on March 3, 2026. They will host a live presentation and investor meetings, with a replay later available online, underscoring Avacta’s efforts to raise its profile among healthcare investors and communicate progress on its oncology pipeline.

The most recent analyst rating on (GB:AVCT) stock is a Hold with a £48.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.

Spark’s Take on GB:AVCT Stock

According to Spark, TipRanks’ AI Analyst, GB:AVCT is a Neutral.

Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.

To see Spark’s full report on GB:AVCT stock, click here.

More about Avacta Group plc

Avacta Therapeutics, a subsidiary of Avacta Group plc, is a clinical-stage biopharmaceutical company focused on oncology. It is developing the proprietary pre|CISION platform, a tumor-activated drug delivery technology that uses fibroblast activation protein to concentrate potent cancer therapies in solid tumors while limiting exposure in healthy tissues. Its pipeline includes pre|CISION peptide drug conjugates and Affimer drug conjugates designed to improve efficacy and reduce toxicity compared with traditional antibody drug conjugates.

Average Trading Volume: 2,337,049

Technical Sentiment Signal: Sell

Current Market Cap: £253.7M

See more data about AVCT stock on TipRanks’ Stock Analysis page.